Author: "Anne-Bénédicte Duval-Modeste" / Topic: medicine.medical_specialty - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Anne-Bénédicte Duval-Modeste"' showing total 30 results

Start Over Author "Anne-Bénédicte Duval-Modeste" Topic medicine.medical_specialty

30 results on '"Anne-Bénédicte Duval-Modeste"'

1. Intralesional rituximab treatment for atypical refractory granuloma faciale

Author: G Arhant, M Mouthon, L Cellier, Pascal Joly, Anne Dompmartin, R Sabatier, F. Comoz, E. Joly, and Anne-Bénédicte Duval-Modeste
Subjects: medicine.medical_specialty, Granuloma, Skin Neoplasms, business.industry, Dermatology, medicine.disease, Refractory, medicine, Humans, Granuloma faciale, IgG4-related disease, Rituximab, Connective Tissue Diseases, business, Facial Dermatoses, medicine.drug
Published: 2021
Full Text: View/download PDF

2. Effectiveness and safety of nivolumab in patients with advanced melanoma: A multicenter, observational study

Author: Stéphane Dalle, Patrick Combemale, Yannick Le Corre, Caroline Dutriaux, E. Varey, Nathalie Beneton, Thomas Jouary, Caroline Robert, Henri Montaudié, Jean Philippe Arnault, Sandrine Monestier, Marie Thérèse Leccia, Sandrine Mansard, Laurent Mortier, Amir Khammari, Anne-Bénédicte Duval Modeste, François Skowron, Nicolas Meyer, Brigitte Dréno, Nabahet Ameur, Bernard Guillot, Philippe Saiag, E. Hainaut, Sophie Dalac-Rat, Service de dermatologie, vénéreologie et cancérologie cutanée [Hôpital de la Timone - APHM], Hôpital de la Timone [CHU - APHM] (TIMONE)-Assistance Publique - Hôpitaux de Marseille (APHM)-Aix Marseille Université (AMU), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 (ONCO-THAI), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille, CHU Bordeaux [Bordeaux], Service de Dermatologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire [Grenoble] (CHU), CHU Clermont-Ferrand, Hôpital Archet 2 [Nice] (CHU), Biomarqueurs et essais cliniques en Cancérologie et Onco-Hématologie (BECCOH), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Saclay, Hôpital Ambroise Paré [AP-HP], Centre Léon Bérard [Lyon], CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Hôpital Charles Nicolle [Rouen], Centre Hospitalier Le Mans (CH Le Mans), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR), Service de dermatologie [CHU d'Amiens-Picardie], CHU Amiens-Picardie, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Centre hospitalier de Pau, Centre d’Investigation Clinique de Nantes (CIC Nantes), Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre hospitalier universitaire de Nantes (CHU Nantes), Amgen Bristol-Myers Squibb, BMS Pfizer Novartis Roche AbbVie Les Laboratories Pierre Fabre LEO Pharma Research Foundation, Sandrine Monestier has received consultant fees from BMS and Roche, support for travel/congress from BMS, Roche, GSK and MSD, and has participated as an investigator on clinical trials for BMS, Roche‐ Genentech, GSK, Amgen, Novartis, MSD, Merck‐Serono and Astra Zeneca. Stéphane Dalle has received congress invitation and fees coverage from BMS, Pierre Fabre and MSD, translational study grant to institution from BMS and MSD. Laurent Mortier received support to travel to medical congresses from BMS, MSD, Roche and Novartis. Caroline Dutriaux has been a member of advisory boards and received consultancy fees from BMS, MSD, Pierre Fabre and Novartis. Sophie Dalac‐Rat has received honoraria, provided consultancy and been on advisory committees for BMS, MSD, Novartis and Sun pharma. Nicolas Meyer has received honoraria from Sun Pharma, Roche, Novartis and Pierre Fabre, research funding from BMS, MSD, provided consultancy to BMS, MSD, Roche, Novartis and Pierre Fabre, been on advisory committees for Amgen, Incyte, BMS, MSD, Roche, Novartis and Pierre Fabre. Sandrine Mansard has worked on advisory boards for BMS and Novartis, has received congress and travel fees from BMS and Pierre Fabre. Henri Montaudié has worked on advisory boards for BMS, MSD, Pierre Fabre and Novartis, provided consultancy to MSD and Pierre Fabre, received honoraria from BMS, MSD, Pierre Fabre and Novartis, received research funding from BMS and Leo Pharma. Philippe Saiag has received personal fees from Amgen, Bristol‐Myers Squibb, MSD, Merck‐Serono, Pfizer, Roche‐Genentech, Pierre Fabre and Novartis, received nonfinancial support from Bristol‐Myers Squibb, MSD, Roche‐Genentech and Novartis, received a funding grant from Roche‐Genentech. Patrick Combemale has worked on advisory committees for Roche, Pierre Fabre and AstraZenecca. Ewa Hainaut has been a speaker for BMS, Novartis and Sanofi, worked on advisory boards for Novartis and Sanofi, received research funding from Abbvie. Caroline Robert has received consultancy fees from BMS, MSD, Roche, Novartis, Sanofi, Pierre Fabre and Amgen. Yannick Le Corre has provided consultancy to BMS, MSD and Novartis, worked on advisory boards for BMS, MSD, Novartis and Pierre Fabre, received congress invitation from BMS, MSD and Novartis, has received honoraria from BMS. Nabahet Ameur is employee of Bristol‐Myers‐Squibb. Brigitte Dréno has received research funding from Amgen, BMS, Novartis and Roche, provided consultancy to BMS and Roche, worked on advisory boards for BMS, Roche and Pierre Fabre. Jean Philippe Arnault has been a speaker for BMS. Marie Thérèse Leccia, Bernard Guillot, François Skowron, Anne‐Bénédicte Duval Modeste, Nathalie Bénéton, Thomas Jouary, Emilie Varey, and Amir Khammari have no conflicts of interest to declare., Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Rouen, Normandie Université (NU)-Normandie Université (NU), HAL UVSQ, Équipe, and Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Subjects: Male, advanced melanoma, safety, Cancer Research, medicine.medical_specialty, real-world, Databases, Factual, effectiveness, [SDV.CAN]Life Sciences [q-bio]/Cancer, 03 medical and health sciences, 0302 clinical medicine, Antineoplastic Agents, Immunological, [SDV.CAN] Life Sciences [q-bio]/Cancer, Internal medicine, medicine, Humans, In patient, Adverse effect, Melanoma, Advanced melanoma, Aged, Retrospective Studies, Aged, 80 and over, nivolumab, business.industry, Incidence (epidemiology), Retrospective cohort study, Middle Aged, Survival Analysis, 3. Good health, Clinical trial, Treatment Outcome, Oncology, 030220 oncology & carcinogenesis, Observational study, France, Nivolumab, business
Abstract: International audience; This retrospective observational study aimed to determine the effectiveness, safety and patterns of the use of nivolumab in patients with advanced melanoma in real-world clinical practice in France using data from a Temporary Authorization for Use Program (ATU). Data were collected from patients with unresectable or metastatic melanoma enrolled in a French national database (Réseau pour la Recherche et l'Investigation Clinique sur le Mélanome: Ric-Mel) and treated with nivolumab during the ATU program (12 September 2014 to 31 August 2015). The primary objectives of the study were to evaluate the effect of patient characteristics on clinical response and overall survival (OS). Among 400 included patients (median age 66 years), the majority (83%) received nivolumab as second- or subsequent-line therapy. The median durations of progression-free survival and OS were 3.3 and 14.1 months, respectively, and 31.6% of patients achieved an objective response with a median duration of 20.1 months (range: 0-34.7). The safety profile of nivolumab was manageable and consistent with those of previous clinical trials, with an incidence of grade 3-5 adverse events of 13.8%. The safety and effectiveness of nivolumab in patients with advanced melanoma in real-world clinical practice in France were in line with the data reported in the Phase 3 trials CheckMate 066 and 037 of nivolumab in this patient population.
Published: 2021
Full Text: View/download PDF

3. Cetuximab is efficient and safe in patients with advanced cutaneous squamous cell carcinoma: a retrospective, multicentre study

Author: Gilles Poissonnet, Alexandra Picard-Gauci, Laurent Mortier, Julien Viotti, Julie De Quatrebarbes, Regis Kaphan, Maria Kogay, Henri Montaudié, Caroline Robert, Caroline Dutriaux, Anne-Bénédicte Duval-Modeste, Nicolas Dupin, Stéphane Dalle, Andrea Stefan, Patrick Combemale, Florence Brunet-Possenti, and Frederic Peyrade
Subjects: 0301 basic medicine, Oncology, medicine.medical_specialty, Cutaneous squamous cell carcinoma, cutaneous squamous cell carcinoma, medicine.medical_treatment, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, cetuximab, medicine, Clinical endpoint, Epidermal growth factor receptor, Adverse effect, Chemotherapy, Cetuximab, biology, business.industry, Radiation therapy, 030104 developmental biology, 030220 oncology & carcinogenesis, Toxicity, biology.protein, epidermal growth factor receptor, business, Research Paper, medicine.drug
Abstract: There is no standard of care for unresectable cutaneous squamous cell carcinoma (cSCC). Chemotherapy, alone or combined with radiotherapy, is commonly used mostly as palliative treatment; moreover, its poor safety profile limits its use most of the time, especially in elderly patients. Thus, alternative options are needed. Targeted molecular inhibitors, such as the epidermal growth factor receptor inhibitor cetuximab, seem promising, but data are limited. We retrospectively evaluated clinical outcomes of cetuximab as a single agent in this indication. The primary endpoint was the Disease Control Rate (DCR) at 6 weeks according to RECIST criteria. Secondary endpoints included DCR at 12 weeks, objective response rate (ORR) at 6 and 12 weeks, progression-free-survival (PFS), overall survival (OS), and safety profile. Fifty-eight patients received cetuximab as monotherapy. The median age was 83.2 (range, 47.4 to 96.1). The majority of patients was chemotherapy naïve. The median follow-up was 11.7 months (95% CI: 9.6-30.1). The DCR at 6 and 12 weeks was 87% and 70%, respectively. The ORR was 53% and 42%, respectively, at 6 and 12 weeks. The median PFS and OS were 9.7 months (95% CI: 4.8-43.4) and 17.5 months (95% CI: 9.4-43.1), respectively. Fifty-one patients (88%) experienced toxicity, and 67 adverse events related to cetuximab occurred. Most of them (84%) were grade 1 to 2. Our study shows that cetuximab is safe and efficient for the treatment of patients, even elderly ones, with advanced cSCC. These results indicate that cetuximab is a promising agent to test in new combinations, especially with immune checkpoint inhibitors such as anti–PD-1 agents.
Published: 2020
Full Text: View/download PDF

4. Lymphome cérébral primitif après immunothérapie d’un mélanome métastatique

Author: Pascal Joly, M.-H. Commin, Fabrice Jardin, F. Marguet, M. Castel, A. Deschamps-Huvier, Anne-Bénédicte Duval-Modeste, and C. Cotten
Subjects: Gynecology, 030207 dermatology & venereal diseases, 03 medical and health sciences, medicine.medical_specialty, 0302 clinical medicine, business.industry, medicine, Dermatology, business
Abstract: Resume Introduction Les anticorps anti-PD-1 et anti-CTLA-4 sont des inhibiteurs de checkpoints du systeme immunitaire utilises dans le traitement du melanome. Les anti-PD-1 ont ete recemment valides comme traitement du lymphome de Hodgkin. Le lymphome cerebral primitif est une forme rare de lymphome non hodgkinien pour lequel il existe peu de traitements efficaces. Des etudes ont montre l’efficacite des anticorps anti-PD-1 dans des lymphomes non hodgkiniens, dont le lymphome cerebral primitif. Observation Un patient de 59 ans presentait un melanome metastatique traite depuis plusieurs mois par immunotherapie (anti-CTLA-4, puis anti-PD-1). Apres 28 cures, le pembrolizumab etait arrete devant une remission complete du melanome. Une hemiparesie gauche survenait deux mois apres l’arret de l’immunotherapie, revelant un lymphome cerebral primitif evolutif. Une chimiotherapie par methotrexate a hautes doses etait debutee, sans efficacite. Malgre une seconde ligne de traitement par chimiotherapie R-ICE (rituximab-ifosfamide, carboplatine et etoposide), le patient decedait des suites de son lymphome cerebral. Discussion Plusieurs hypotheses peuvent etre avancees quant a un lien eventuel entre l’immunotherapie et la survenue du lymphome cerebral. Nous pouvons evoquer le controle d’un lymphome meconnu par l’immunotherapie, suivi d’un echappement et d’une progression rapide a l’arret du traitement, mais l’hypothese d’un lymphome induit par l’immunotherapie n’est pas exclue. Enfin, l’immunotherapie peut n’avoir joue aucun role, l’association entre lymphome et melanome etant bien connue. Conclusion Malgre l’impossibilite de conclure sur l’imputabilite de l’immunotherapie dans la survenue du lymphome cerebral primitif, ce cas souleve de nombreuses questions sur le possible role de l’immunotherapie dans la survenue de cancers secondaires, dont des lymphomes.
Published: 2019
Full Text: View/download PDF

5. Cemiplimab for locally advanced and metastatic cutaneous squamous-cell carcinomas: Real-life experience from the French CAREPI study group

Author: Pierre-Emmanuel Stoebner, Christophe Bedane, A. Jannic, Marc Dumas, Marie Moncourier, Sandrine Mansard, Anne-Bénédicte Duval-Modeste, David Solub, Sophie Darras, Suzanne Devaux, Julia Sanchez, Nicolas Meyer, Laurent Misery, Valentine Heidelberger, Raoul Triller, Ingrid Kupfer-Bessaguet, Nathalie Beneton, Florence Brunet-Possenti, Gaëlle Quéreux, E. Maubec, Sophie Dalac, François Skowron, Safia Abed, Caroline Gaudy-Marqueste, Laurent Mortier, Monica Dinulescu, F. Herms, Lucie Peuvrel, Marouane Boubaya, Candice Hober, Pierre Guillet, Mahtab Samimi, Yves Reguerre, Nicolas Poulalhon, Anne Pham-Ledard, Stéphanie Catala, Eve-Marie Neidhardt, Romain Lesbazeilles, Jean-Philippe Arnault, Brigitte Dréno, Olivier Collard, Philippe Celerier, Julie De Quatrebarbes, Youssef Tazi, Pierre Combe, Caroline Jacobzone, Élodie Archier, F. Aubin, Dominique Spaeth, Clémence Berthin, Nora Kramkimel, Florent Grange, Candice Lesage, Lisa Fredeau, A. Schoeffler, Marc Pracht, Bertille Bonniaud, Laure Cesaire, Maxime Etienne, Olivier Lauche, CHU Lille, Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Bordeaux [Bordeaux], Université de Bordeaux (UB), Hopital Saint-Louis [AP-HP] (AP-HP), Hôpital Saint-Louis de La Rochelle (CH La Rochelle), Université de Bourgogne (UB), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre Hospitalier Le Mans (CH Le Mans), Hôpital Pontchaillou, Hôpital Henri Mondor, Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Hôpital Côte de Nacre [CHU Caen], CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Centre Léon Bérard [Lyon], Hôpital Saint-Joseph [Marseille], Centre hospitalier universitaire de Nantes (CHU Nantes), Université de Nantes (UN), Centre d’Investigation Clinique de Nantes (CIC Nantes), Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre hospitalier universitaire de Nantes (CHU Nantes), Clinical and Translational Research in Skin Cancer (CRCINA-ÉQUIPE 2), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Hôpital Cochin [AP-HP], Centre Hospitalier Universitaire de Reims (CHU Reims), Centre Hospitalier de Valence (CH DE VALENCE), Centre hospitalier de Valence, CH Annecy Genevois, CHU de Nîmes, Institut des Biomolécules Max Mousseron [Pôle Chimie Balard] (IBMM), Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM)-Institut de Chimie du CNRS (INC)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), CHU Amiens-Picardie, Hopital d'instruction des armées Sainte-Anne [Toulon] (HIA), CH Boulogne sur Mer, Hôpital Robert Ballanger [Aulnay-sous-Bois], Centre Hospitalier de la Côte Basque (CHCB), Centre Hospitalier Universitaire [Grenoble] (CHU), Université de Bretagne Occidentale, CHU Clermont-Ferrand, Centre Hospitalier Intercommunal de Cornouaille (CHIC), Centre Hospitalier Intercommunal de Cornouaille [Quimper] (CHI Cornouaille [Quimper]), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Centre Hospitalier Georges Renon [Niort] (CH Georges Renon Niort), Clinique Saint Pierre, Perpignan, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Infectiologie et Santé Publique (UMR ISP), Université de Tours (UT)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Clinique Sainte Anne [Strasbourg], Centre d'Oncologie de Gentilly, Institut de Cancérologie de la Loire Lucien Neuwirth, Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Institut hospitalier Franco-Britannique [Levallois-Perret], CH René Dubos, Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER, Pôle Santé Léonard de Vinci, Partenaires INRAE, Centre Hospitalier Universitaire de La Réunion (CHU La Réunion), Centre hospitalier régional Metz-Thionville (CHR Metz-Thionville), CHU Limoges, Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 (ONCO-THAI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), UFR Santé, Médecine et Biologie Humaine (UFR SMBH), Université Sorbonne Paris Nord, Toxicité environnementale, cibles thérapeutiques, signalisation cellulaire (T3S - UMR_S 1124), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), CHU Toulouse [Toulouse]-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre hospitalier universitaire de Toulouse - CHU Toulouse, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC)-Université de Montpellier (UM)-Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM), Le CHCB, Centre Hospitalier de la Côte Basque, Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Toulouse [Toulouse], Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPC), Université de Tours-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille, and Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP)
Subjects: Cancer Research, medicine.medical_specialty, cutaneous squamous cell carcinoma, Locally advanced, Best Overall Response, [SDV.CAN]Life Sciences [q-bio]/Cancer, Gastroenterology, Article, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Overall survival, Medicine, Adverse effect, Group performance, RC254-282, Immune status, business.industry, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Mean age, medicine.disease, chronic dermatosis, Toxic epidermal necrolysis, 3. Good health, immunocompromised, real-life setting, Oncology, 030220 oncology & carcinogenesis, PD-1–blocking antibody, cemiplimab, business, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology
Abstract: Although cemiplimab has been approved for locally advanced (la) and metastatic (m) cutaneous squamous-cell carcinomas (CSCCs), its real-life value has not yet been demonstrated. An early-access program enrolled patients with la/mCSCCs to receive cemiplimab. Endpoints were best overall response rate (BOR), progression-free survival (PFS), overall survival (OS), duration of response (DOR) and safety. The 245 patients (mean age 77 years, 73% male, 49% prior systemic treatment, 24% immunocompromised, 27% Eastern Cooperative Oncology Group performance status (PS) ≥ 2) had laCSCCs (35%) or mCSCCs (65%). For the 240 recipients of ≥1 infusion(s), the BOR was 50.4% (complete, 21%, partial, 29%). With median follow-up at 12.6 months, median PFS was 7.9 months, and median OS and DOR were not reached. One-year OS was 73% versus 36%, respectively, for patients with PS &lt, 2 versus ≥ 2. Multivariate analysis retained PS ≥ 2 as being associated during the first 6 months with PFS and OS. Head-and-neck location was associated with longer PFS. Immune status had no impact. Severe treatment-related adverse events occurred in 9% of the patients, including one death from toxic epidermal necrolysis. Cemiplimab real-life safety and efficacy support its use for la/mCSCCs. Patients with PS ≥ 2 benefited less from cemiplimab, but it might represent an option for immunocompromised patients.
Published: 2021
Full Text: View/download PDF

6. Panniculitis in a Woman With Opportunistic Pulmonary Coinfection by Pneumocystis jirovecii and Cryptococcus neoformans: 18F-FDG PET/CT Revealing the Infection and Assessing Treatment Response

Author: Stéphane Dominique, Philippe Courville, Pierre Vera, Anne-Bénédicte Duval-Modeste, Hamza Regaieg, and Billal Tedbirt
Subjects: Pathology, medicine.medical_specialty, Opportunistic Infections, Pneumocystis carinii, 030218 nuclear medicine & medical imaging, 03 medical and health sciences, 0302 clinical medicine, Fluorodeoxyglucose F18, Psoriasis, Positron Emission Tomography Computed Tomography, medicine, Pneumocystis jirovecii, Humans, Radiology, Nuclear Medicine and imaging, Cryptococcus neoformans, Lung, medicine.diagnostic_test, biology, business.industry, Coinfection, Pneumonia, Pneumocystis, General Medicine, Cryptococcosis, Middle Aged, medicine.disease, biology.organism_classification, 3. Good health, Pneumonia, Bronchoalveolar lavage, medicine.anatomical_structure, Treatment Outcome, 030220 oncology & carcinogenesis, Female, Panniculitis, business
Abstract: A 56-year-old woman, with history of psoriasis well controlled on ustekinumab, underwent 18F-FDG PET/CT to explore first onset of histologically proven skin panniculitis of unknown origin. PET/CT showed high uptake in panniculitis lesions in limbs and in a lung opacity suggestive of pneumonia. Based on PET/CT findings, a bronchoalveolar lavage revealed pulmonary coinfection by Pneumocystis jirovecii and Cryptococcus neoformans. Thus, hematogenous dissemination of infection was suspected as etiology of panniculitis. She was treated with fluconazole and trimethoprim-sulfamethoxazole, leading to total resolution of skin lesions. Posttherapeutic PET/CT showed complete metabolic response of skin and pulmonary lesions.
Published: 2020

7. Anti-PD-1 induced collagenous colitis in metastatic melanoma: a rare severe adverse event

Author: Julie Bouteiller, Aurélie Deschamps-Huvier, Raphaël Janela-Lapert, Anne-Bénédicte Duval-Modeste, and Pascal Joly
Subjects: 0301 basic medicine, Male, Cancer Research, medicine.medical_specialty, Loperamide, Skin Neoplasms, medicine.drug_class, Colitis, Collagenous, Dermatology, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Microscopic colitis, Internal medicine, Medicine, Humans, Colitis, Adverse effect, Immune Checkpoint Inhibitors, Melanoma, Aged, Collagenous colitis, business.industry, medicine.disease, Diarrhea, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Corticosteroid, Immunotherapy, Nivolumab, medicine.symptom, business, medicine.drug
Abstract: Immunotherapy has improved the overall survival of patients with metastatic melanoma. Inflammatory bowel disease-like colitis is the most frequent gastrointestinal serious adverse event in patients treated with immune-checkpoint inhibitors. Collagenous colitis is microscopic colitis. Only two cases of immune-checkpoint inhibitors induced collagenous colitis have been reported. A man in his early 70s was referred for a metastatic melanoma treated with nivolumab as the fourth line of treatment. During the 21st cycle, the patient complained of watery, nonbloody diarrhea (around six times per day). Rectosigmoidoscopy showed no mucosal lesion. A thickened subepithelial collagen band was evidenced by trichrome staining, which was suggestive of collagenous colitis. Nivolumab was stopped and the patient was treated with budesonide 9 mg/day in combination with loperamide and cholestyramine, leading to improvement of diarrhea. However, worsening of digestive symptoms during tapering of corticosteroid dose required the permanent discontinuation of nivolumab. Due to the very low number of cases reported to date and their different evolution under corticosteroids, it is not clear whether or not immune checkpoint inhibitors can be restarted in these patients.
Published: 2020

8. Controlling the digital ulcerative disease in systemic sclerosis is associated with improved hand function

Author: Pierre Clerson, Aurélie Khau Van Kien, Alice Bérezné, Virginie Gressin, Christian Agard, Catherine Lok, Patrick Jego, Luc Mouthon, Agnès Sparsa, Elisabeth Diot, Anne-Bénédicte Duval-Modeste, Eve Puzenat, Patrick H. Carpentier, Marie-Aleth Richard, and Eric Hachulla
Subjects: Adult, Endothelin Receptor Antagonists, Male, medicine.medical_specialty, Visual analogue scale, Disease, Severity of Illness Index, Disability Evaluation, 03 medical and health sciences, 0302 clinical medicine, Rheumatology, Quality of life, Internal medicine, Skin Ulcer, medicine, Clinical endpoint, Humans, In patient, Prospective Studies, 030212 general & internal medicine, Aged, 030203 arthritis & rheumatology, Sulfonamides, Scleroderma, Systemic, Hand function, business.industry, Bosentan, Middle Aged, Hand, Surgery, Treatment Outcome, Anesthesiology and Pain Medicine, Quality of Life, Female, Observational study, business, medicine.drug
Abstract: Ischemic digital ulcers (DU) represent a major complication of systemic sclerosis (SSc). We investigated the impact of controlling the ulcerative disease on disability, pain, and quality of life in SSc patients receiving bosentan.ECLIPSE (Study AC-052-517) is a 2-year prospective, multicenter, and observational study. Patients with SSc who experienced at least 1 DU in the previous year and received bosentan were included between October 2009 and March 2011. Disability scores [Cochin Hand Function Scale (CHFS) and Health Assessment Questionnaire Disability Index (HAQ-DI)], pain scores (visual analog scale), and quality-of-life scores (SF-36) were collected at inclusion and 1 year later (primary endpoint). A controlled ulcerative disease was defined by the absence of ongoing/new DU episode between inclusion and 1-year follow-up.Data were available at 1 year for 120 patients out of 190 included. During follow-up, 46 (38.3%) patients experienced a new DU episode. The number of DU per patient decreased from 1.4 ± 1.8 at inclusion to 0.6 ± 1.6 (p0.0001) at 1 year. Disability scores decreased from 1.0 ± 0.7 to 0.9 ± 0.7 (p = 0.04) for the HAQ-DI and from 29 ± 20 to 25 ± 20 (p = 0.005) for the CHFS; the pain score decreased from 4.3 ± 3.1 to 2.9 ± 2.8 (p0.0001). This improvement was attributed to patients with a controlled ulcerative disease (48.3%), who significantly improved HAQ-DI (p = 0.04), CHFS (p = 0.04), and pain score (p = 0.046).In patients with SSc, control of the ulcerative disease for 1 year was associated with significant attenuation of hand disability.
Published: 2017
Full Text: View/download PDF

9. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort

Author: A. Schoeffler, Ziad Reguiai, Audrey Lasek, Anne-Sophie Dillies, Jonathan Giovannelli, Nadia Raison-Peyron, Marie-Christine Ferrier le Bouedec, Aurélie Du Thanh, Sarah Faiz, Anne Dompmartin, Laurent Misery, Marie-Aleth Richard, J. Delaunay, Jean-Philippe Lacour, Sandrine Rappelle-Duruy, Jean-Philippe Arnault, Céline Podevin, Anne-Bénédicte Duval-Modeste, Jean-David Bouaziz, Angèle Soria, Amélie Walter-Lepage, Julien Sénéchal, Delphine Staumont-Sallé, François Aubin, Catherine Droitcourt, N. Bellon, Sébastien Barbarot, Stéphane Barete, Florence Tetart, Marie Jachiet, Emmanuel Mahé, Nathalie Beneton, Edouard Begon, Audrey Nosbaum, A. Valois, C. Morice, Service de Dermatologie, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Lille Inflammation Research International Center - U 995 (LIRIC), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de Dermatologie [AP-HP Hôpital Saint-Louis], Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Polyclinique Courlancy (PC), Polyclinique de Courlancy, Immunologie de l'allergie cutanée et vaccination – Immunology of skin allergy and vaccination, Centre International de Recherche en Infectiologie - UMR (CIRI), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôpital Saint Vincent de Paul de Lille, Groupement des Hôpitaux de l'Institut Catholique de Lille (GHICL), Université catholique de Lille (UCL)-Université catholique de Lille (UCL), Université de Clermont-Ferrand, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Service de dermatologie [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Service de Dermatologie [Rouen], Hôpital Charles Nicolle [Rouen], Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Service de dermatologie, Hôpital Augustin Morvan-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Département de dermatologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Service de Dermatologie [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Service de Dermatologie [Rennes] = Dermatology [Rennes], CHU Pontchaillou [Rennes], CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre d'Immunologie et des Maladies Infectieuses (CIMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Service de dermatologie [CHU d'Amiens-Picardie], CHU Amiens-Picardie, Département de dermatologie, CHU Angers, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Service de Dermatologie et pathologies vasculaires [CH Argenteuil], Centre Hospitalier Victor Dupouy, Centre d'études et de recherche sur les services de santé et la qualité de vie (CEReSS), Aix Marseille Université (AMU), Centre hospitalier régional Metz-Thionville (CHR Metz-Thionville), Service de Dermatologie [Nice], Hôpital Archet 2 [Nice] (CHU), Centre Hospitalier René Dubos [Pontoise], CHU La Milétrie, Université de Picardie Jules Verne (UPJV), Service de Dermatologie, Hôpital Joseph Imbert, Centre Hospitalier d'Arles, CHU Pitié-Salpêtrière [AP-HP], Service de dermatologie [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Le Mans (CH Le Mans), Hôpital d'Instruction des Armées Sainte Anne, Service de Santé des Armées, Neurofibromatosis Clinic, Centre hospitalier universitaire de Nantes (CHU Nantes), Biothérapies des maladies génétiques et cancers, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), CCSD, Accord Elsevier, Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Groupe Hospitalier de l'Institut Catholique de Lille (GHICL), Normandie Université (NU)-Normandie Université (NU)-Hôpital Charles Nicolle [Rouen], Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Hôpital Augustin Morvan, Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Hôpital Saint-Jacques-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre d'Immunologie et de Maladies Infectieuses (CIMI), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
Subjects: Adult, Male, medicine.medical_specialty, Injections, Subcutaneous, [SDV]Life Sciences [q-bio], Kaplan-Meier Estimate, Dermatology, Antibodies, Monoclonal, Humanized, Risk Assessment, Severity of Illness Index, Eczema Area and Severity Index, Drug Administration Schedule, Dermatitis, Atopic, Cohort Studies, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Interquartile range, Internal medicine, dupilumab, medicine, conjunctivitis, Humans, SCORAD, Adverse effect, Proportional Hazards Models, Retrospective Studies, Dose-Response Relationship, Drug, medicine.diagnostic_test, business.industry, Antibodies, Monoclonal, Atopic dermatitis, Dermatology Life Quality Index, medicine.disease, adultsatopic dermatitis, Dupilumab, 3. Good health, [SDV] Life Sciences [q-bio], 030220 oncology & carcinogenesis, Cohort, biotherapy, Female, France, Patient Safety, business, eosinophilia
Abstract: International audience; BackgroundDupilumab is the first biologic available to treat atopic dermatitis (AD). Its effectiveness and safety were demonstrated in clinical trials.ObjectiveWe sought to assess the effectiveness and safety of dupilumab in adults with AD in a real-life French multicenter retrospective cohort.MethodsWe included patients treated during March 2017-April 2018. Efficacy outcomes, including Scoring Atopic Dermatitis (SCORAD) and Eczema Area and Severity Index (EASI) scores, were collected at baseline and 3 months when available. Adverse events (AEs) were recorded at follow-up.ResultsWe included 241 patients. The median ± interquartile range (IQR) follow-up time was 3.8 ± 3.7 months. A ≥75% improvement in SCORAD was achieved in 27 of 163 (16.6%) patients, and a ≥75% improvement in EASI was achieved in 40 of 82 (48.8%) patients. The median SCORAD and EASI scores at 3 months were significantly lower than those at baseline (SCORAD ± IQR, 25 ± 21 vs 56 ± 27.4, P < 10−9 and EASI ± IQR, 4.1 ± 6.8 vs 17.9 ± 15.4, P < 10−9, respectively). Conjunctivitis was reported in 84 of 241 (38.2%) patients. The proportion with eosinophilia (>500 cells/mm3) during follow-up (57%) was higher than that at baseline (33.7%) (n = 172, P < 10−6). Dupilumab was stopped in 42 cases; 27 patients stopped because of AEs.LimitationsNo control group, missing data.ConclusionThis real-life study demonstrated a similar dupilumab effectiveness as that seen in clinical trials, but it also revealed a higher frequency of conjunctivitis and eosinophilia.
Published: 2019
Full Text: View/download PDF

10. A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, Leg Type

Author: Reda Bouabdallah, Laurent Mortier, Stéphane Dalle, Pascal Joly, Eve Maubec, Martine Bagot, N. Bonnet, Saskia Ingen-Housz-Oro, Stéphane Barete, Béatrice Vergier, Gaëlle Quéreux, Jean-Philippe Merlio, Anne-Bénédicte Duval-Modeste, D. Mermin, Marie Beylot-Barry, Aline Maillard, Florent Grange, Pierre-Julien Vially, Eric Frison, Caroline Ram-Wolff, Audrey Gros, Anne Pham-Ledard, Isabelle Templier, CHU Bordeaux [Bordeaux], Université de Bordeaux (UB), Unité de Soutien Méthodologique à la Recherche Clinique (USMR), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Service de dermatologie [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Centre Hospitalier Universitaire de Lille (CHU de Lille), CHU Henri Mondor, Département de pathologie [Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre de référence des mastocytoses (CEREMAST), CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de dermatologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Institut Mondor de recherche biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Département de Dermatologie [CHU de Reims], Centre Hospitalier Universitaire de Reims (CHU Reims), Physiopathologie du cancer du foie, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de Santé Publique, d'Epidémiologie et de Développement (ISPED), Université Bordeaux Segalen - Bordeaux 2, Laboratoire d'Histologie et de Pathologie moléculaire des tumeurs, Université Bordeaux Segalen - Bordeaux 2-EA 2406, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre de référence des mastocytoses, Institut de Génomique Fonctionnelle (IGF), Université de Montpellier (UM)-Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Montpellier 2 - Sciences et Techniques (UM2)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris]-Université Paris Diderot - Paris 7 (UPD7), Centre de Recherche en Cancérologie / Nantes - Angers (CRCNA), Centre hospitalier universitaire de Nantes (CHU Nantes)-Faculté de Médecine d'Angers-Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Centre National de la Recherche Scientifique (CNRS)-Hôpital Laennec-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôtel-Dieu de Nantes, and Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
Subjects: 0301 basic medicine, Male, medicine.medical_specialty, Skin Neoplasms, Biopsy, [SDV]Life Sciences [q-bio], Dermatology, Biochemistry, Gastroenterology, Disease-Free Survival, 03 medical and health sciences, 0302 clinical medicine, Refractory, Internal medicine, medicine, Clinical endpoint, Humans, Immunologic Factors, Progression-free survival, B-cell lymphoma, Molecular Biology, Lenalidomide, ComputingMilieux_MISCELLANEOUS, Aged, Skin, Aged, 80 and over, Leg, Dose-Response Relationship, Drug, business.industry, Remission Induction, Cell Biology, medicine.disease, 3. Good health, Lymphoma, Survival Rate, 030104 developmental biology, Treatment Outcome, 030220 oncology & carcinogenesis, Rituximab, Female, France, Lymphoma, Large B-Cell, Diffuse, Neoplasm Recurrence, Local, business, Diffuse large B-cell lymphoma, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology, medicine.drug
Abstract: Although the combination of rituximab and polychemotherapy has improved prognosis of primary cutaneous diffuse large B-cell lymphoma, leg type, the advanced age of patients limits therapeutic options in relapsing/refractory cases. A multicenter, single-arm, phase II trial was conducted to assess the benefits and safety of lenalidomide in refractory/relapsing primary cutaneous diffuse large B-cell lymphoma, leg type. The primary endpoint was the 6-month overall response rate. Secondary endpoints were 12-month overall response rate, overall and specific survival, duration of response, progression-free survival, safety, and identification of prognostic factors. Among the 19 patients included, the 6-month overall response rate was 26.3% (90% confidence interval [CI] = 11–47.6), including four complete responses and one partial response. At 12 months, there were still two complete responses and one partial response. Median progression-free survival was 4 months. Median overall and specific survivals were 19.4 and 23.8 months, respectively. Reduced doses tended to be associated with higher 6-month overall response rate and progression-free survival. Absence of the MYD88L265P mutation was associated with a higher overall response under treatment (80.0% vs. 33.3%; P = 0.05). The most common grade 3 adverse events were hematologic. Two grade 5 adverse events occurred (sepsis and pulmonary embolism). Lenalidomide at reduced doses may allow prolonged responses in a few patients and represents a therapeutic option in relapsing/refractory primary cutaneous diffuse large B-cell lymphoma, leg type.
Published: 2018
Full Text: View/download PDF

11. Simultaneous long-lasting regression of multiple nevi and melanoma metastases after ipilimumab therapy

Author: C. Pinard, Marthe Plaquevent, A. Greliak, Pascal Joly, Anne-Bénédicte Duval-Modeste, Service de dermatologie [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Physiopathologie, Autoimmunité, maladies Neuromusculaires et THErapies Régénératrices (PANTHER), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rouen Normandie (UNIROUEN), and Normandie Université (NU)-Normandie Université (NU)
Subjects: Male, 0301 basic medicine, Long lasting, Cancer Research, medicine.medical_specialty, Lung Neoplasms, Skin Neoplasms, Metastatic melanoma, Ipilimumab, Dermatology, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Dysplastic nevus syndrome, medicine, Humans, skin and connective tissue diseases, Melanoma, ComputingMilieux_MISCELLANEOUS, business.industry, Remission Induction, Complete remission, Middle Aged, Prognosis, medicine.disease, Multiple atypical melanocytic nevi, 3. Good health, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, business, Dysplastic Nevus Syndrome, Multiple nevi, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology, medicine.drug
Abstract: We report a case of major regression of multiple atypical melanocytic nevi with a vitiligoid reaction in a patient with metastatic melanoma who achieved long-lasting complete remission after ipilimumab therapy. In 2008, a 54-year-old man presented with a dysplastic nevus syndrome. The patient was diagnosed with a scalp ulcerated melanoma (Breslow index 5.1 mm and Clark level IV), which was removed surgically. Four years later in April 2012, the patient was diagnosed with a right parietal skin metastasis, brain, lymph nodes, and bilateral lung metastases. The patient was first treated with vemurafenib, which had to be stopped because of renal toxicity. Disease stabilization was achieved after the second line of treatment with immunotherapy (ipilimumab, four infusions). However, 6 months later, the lung metastases had progressed. The patient was treated with pulmonary stereotactic radiotherapy associated with a second cycle of ipilimumab. After 6 months, he achieved complete remission. Simultaneously, the patient presented a generalized regression of his nevi with a vitiligoid reaction, or halo nevus, associated with a vitiligo located on the hands and inguinal areas. Vitiligo is a frequent immune-related adverse event of immunotherapy. Immunotherapy-induced halo nevus reaction is much less frequent than vitiligo. It was associated in the two case reports from the literature and in our patient with a quick and long-lasting complete remission of nodes and visceral metastases. Therefore, it might correspond to a stronger antimelanocyte immune reaction, associated with a favorable prognosis. The generalized halo nevi reaction in our patient could be more important because of the two cycles of ipilimumab compared with a single one. In conclusion, this case report suggests that a major regression of multiple nevi on ipilimumab might be associated with immunotherapy response.
Published: 2019
Full Text: View/download PDF

12. Ipilimumab-induced severe meningoradiculitis

Author: Aline Zaréa, Maxime Guillaume, Romain Lefaucheur, Anne-Bénédicte Duval-Modeste, Jasmine Flament, Lou Grangeon, Morgane Lacour, Service de neurologie [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Service de dermatologie [Rouen], Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), and Normandie Université (NU)
Subjects: Oncology, medicine.medical_specialty, business.industry, [SDV]Life Sciences [q-bio], Immune checkpoint inhibitors, MEDLINE, Ipilimumab, General Medicine, 03 medical and health sciences, 0302 clinical medicine, Neurology, 030220 oncology & carcinogenesis, Physiology (medical), Internal medicine, medicine, Surgery, Neurology (clinical), Adverse effect, business, 030217 neurology & neurosurgery, medicine.drug
Published: 2019
Full Text: View/download PDF

13. Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma

Author: Mona Amini-Adle, Pierre Marcant, Yannick Le Corre, Caroline Dutriaux, Nora Kramkimel, Anne Bénédicte Duval Modeste, N. Litrowski, C. Lesage, Nicolas Meyer, Amir Khammari, Caroline Gaudy-Marqueste, C. Mignard, Aurélie Deschamps Huvier, Eve Maubec, Thierry Lesimple, Laurent Mortier, Florence Brunet-Possenti, L. Visseaux, Géraldine Jeudy, A. Stefan, Marie-Françoise Avril, Sabiha Trabelsi, Henri Montaudié, François Aubin, Pascal Joly, Laurent Machet, André Gillibert, Marie-Thérèse Leccia, Jean-Philippe Arnault, Nathalie Beneton, E. Wierzbicka-Hainaut, Dan Lipsker, Service de dermatologie [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU), CHU Bordeaux [Bordeaux], Clinical and Translational Research in Skin Cancer (CRCINA-ÉQUIPE 2), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Service de Dermatologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Cochin [AP-HP], Hôpital Claude Huriez [Lille], CHU Lille, Département d'oncologie médicale [Rennes], CRLCC Eugène Marquis (CRLCC), Département de dermatologie, CHU Marseille, CHU Marseille, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Service de dermatologie (CHRU de Tours), Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Département de dermatologie, Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Hôpital Saint-Jacques-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Département de la santé publique [CHU Strasbourg], CHU Strasbourg, Centre Hospitalier Le Mans (CH Le Mans), Service de Dermatologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Service de dermatologie [CHU d'Amiens-Picardie], CHU Amiens-Picardie, Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Service de dermatologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Service de Dermatologie, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Dermatology Department, AP-HP - Hôpital Bichat - Claude Bernard [Paris], Département Pluridisciplinaire de Médecine, Dermatologie, CHU Grenoble-Hôpital Michallon, Physiopathologie, Autoimmunité, maladies Neuromusculaires et THErapies Régénératrices (PANTHER), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Université Paris Diderot - Paris 7 (UPD7)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Saint-André, Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre hospitalier universitaire de Nantes (CHU Nantes), Centre d’Investigation Clinique de Nantes (CIC Nantes), Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre hospitalier universitaire de Nantes (CHU Nantes), Université Paris Descartes - Paris 5 (UPD5), Hôpital de la Timone [CHU - APHM] (TIMONE), Université Francois Rabelais [Tours], Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (UR 3181) (CEF2P / CARCINO), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre Hospitalier Universitaire de Nice (CHU Nice), Centre méditerranéen de médecine moléculaire (C3M), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA), Centre Hospitalier Universitaire de Reims (CHU Reims), Centre Hospitalier Universitaire [Grenoble] (CHU), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, Hôpital Avicenne [AP-HP], Université Paris 13 (UP13), PRES Université Nantes Angers Le Mans (UNAM), Université de Strasbourg (UNISTRA), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Groupe Hospitalier du Havre Hôpital Jacques Monod (MONTIVILLIERS) (GHH), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), and TAN, Yossan-Var
Subjects: 0301 basic medicine, medicine.medical_specialty, Article Subject, medicine.medical_treatment, Gastroenterology, lcsh:RC254-282, 03 medical and health sciences, 0302 clinical medicine, Interquartile range, Internal medicine, medicine, Stage (cooking), Chemotherapy, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, business.industry, Melanoma, Mucosal melanoma, Retrospective cohort study, Immunotherapy, [SDV.MHEP.DERM] Life Sciences [q-bio]/Human health and pathology/Dermatology, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, 3. Good health, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Cohort, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology, Research Article
Abstract: Background: The objective was to assess the response rate and survival of patients with metastatic mucosal melanoma (MM) and uveal melanoma (UM) treated with anti-CTLA-4 or anti-PD-1 monoclonal antibodies (mAbs).Methods: A multicenter retrospective study was performed in 25 dermatology departments in France. All patients with stage III-C to IV MM or UM who were treated with anti-CTLA-4 or anti-PD-1 mAbs between 2008 and 2016 were included and compared after adjustment for main prognostic factors with a second cohort of patients treated with chemotherapy. Tumor response was evaluated according to RECIST v. 1.1 criteria at Week 12.Results: Four-hundred-and-thirty-nine patients were included, 229 MM (151 immunotherapy, 78 chemotherapy) and 210 UM (100 immunotherapy, 110 chemotherapy). Response rates of MM patients treated with immunotherapy were 18/151 (11.9%; 95% CI:7.2%-18.2%), versus 11/78 (14.1%, 95% CI:7.3%-23.8%) in patients treated with chemotherapy (p=0.87). No tumor response was observed in UM patients treated with immunotherapy, versus 4/110 responses (3.6%, 95% CI:1.0-9.0%) in patients treated with chemotherapy (p=0.15). The adjusted overall survival (OS) of MM patients treated with immunotherapy was longer than that of patients treated with chemotherapy HR=0.62 (95% CI: 0.43-0.91), p=0.014, with an unadjusted median OS of 15.97 months [interquartile range (IQR)=6.89-27.11] and 8.82 months [IQR=5.02-14.92], respectively. The adjusted OS of UM patients treated with immunotherapy was not significantly different from that of patients treated with chemotherapy (HR=0.98, 95% CI: 0.66-1.44) p=0.92, with an unadjusted median OS of 13.38 months [IQR=6.03-29.57] and 11.02 months [IQR=6.13-23.93], respectively.Conclusion: Immunotherapy significantly improves OS for MM. The prognosis of metastatic UM remains poor., Immunotherapy significantly improves OS for MM. The prognosis of metastatic UM remains poor.
Published: 2018
Full Text: View/download PDF

14. Efficacy and Tolerance of Anti-Tumor Necrosis Factor α Agents in Cutaneous Sarcoidosis: A French Study of 46 Cases

Author: Alicia Marquet, Olivier Chosidow, Laurence Bouillet, Didier Bessis, Pascal Joly, Françoise Sarrot-Reynauld, Matthieu Mahévas, Emmanuel Delaporte, Marc Ruivard, Jean-Benoît Monfort, Anne-Bénédicte Duval-Modeste, Olivier Fain, Nicolas Noel, Thierry Passeron, Saskia Ingen-Housz-Oro, Catherine Chapelon-Abric, Diane Bouvry, Sylvain Marchand-Adam, Laurence Fardet, Sébastien Debarbieux, Denis Verrot, Valentine Heidelberger, Pascal Sève, Frédéric Caux, and Dominique Valeyre
Subjects: Adult, Male, medicine.medical_specialty, Adolescent, Databases, Factual, Sarcoidosis, Cutaneous Sarcoidosis, Dermatology, Skin Diseases, 030207 dermatology & venereal diseases, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Recurrence, Internal medicine, Epidemiology, Medicine, Humans, Adverse effect, Aged, 030203 arthritis & rheumatology, business.industry, Tumor Necrosis Factor-alpha, Lupus pernio, Correction, Middle Aged, medicine.disease, Infliximab, 3. Good health, Surgery, Discontinuation, Treatment Outcome, Concomitant, Female, Dermatologic Agents, France, business, Immunosuppressive Agents, medicine.drug, Follow-Up Studies
Abstract: Importance Evidence for the long-term efficacy and safety of anti–tumor necrosis factor α agents (anti-TNF) in treating cutaneous sarcoidosis is lacking. Objective To determine the efficacy and safety of anti-TNF in treating cutaneous sarcoidosis in a large observational study. Design, Setting, and Participants STAT (Sarcoidosis Treated with Anti-TNF) is a French retrospective and prospective multicenter observational database that receives data from teaching hospitals and referral centers, as well as several pneumology, dermatology, and internal medicine departments. Included patients had histologically proven sarcoidosis and received anti-TNF between January 2004 and January 2016. We extracted data for patients with skin involvement at anti-TNF initiation. Main Outcomes and Measures Response to treatment was evaluated for skin and visceral involvement using the ePOST (extra-pulmonary Physician Organ Severity Tool) severity score (from 0 [not affected] to 6 [very severe involvement]). Epidemiological and cutaneous features at baseline, efficacy, steroid-sparing, safety, and relapses were recorded. The overall cutaneous response rate (OCRR) was defined as complete (final cutaneous ePOST score of 0 or 1) or partial response (ePOST drop ≥2 points from baseline but >1 at last follow-up). Results Among 140 patients in the STAT database, 46 had skin involvement. The most frequent lesions were lupus pernio (n = 21 [46%]) and nodules (n = 20 [43%]). The median cutaneous severity score was 5 and/or 6 at baseline. Twenty-one patients were treated for skin involvement and 25 patients for visceral involvement. Reasons for initiating anti-TNF were failure or adverse effects of previous therapy in 42 patients (93%). Most patients received infliximab (n = 40 [87%]), with systemic steroids in 28 cases (61%) and immunosuppressants in 32 cases (69.5%). The median (range) follow-up was 45 (3-103) months. Of the 46 patients with sarcoidosis and skin involvement who were treated with anti-TNF were included, median (range) age was 50 (14-78) years, and 33 patients (72%) were women. The OCRR was 24% after 3 months, 46% after 6 months, and 79% after 12 months. Steroid sparing was significant. Treatment was discontinued because of adverse events in 11 patients (24%), and 21 infectious events occurred in 14 patients (30%). Infections were more frequent in patients treated for visceral involvement than in those treated for skin involvement (n = 12 of 25 [48%] vs n = 2 of 21 [9.5%], respectively; P = .02). The relapse rate was 44% 18 months after discontinuation of treatment. Relapses during treatment occurred in 35% of cases, mostly during anti-TNF or concomitant treatment tapering. Conclusions and Relevance Anti-TNF agents are effective but suspensive in cutaneous sarcoidosis. The risk of infectious events must be considered.
Published: 2017

15. Systemic sclerosis and exposure to heavy metals: A case control study of 100 patients and 300 controls

Author: M. Bubenheim, Pascal Joly, Isabelle Marie, Jacques Benichou, S. Dominique, Anne-Bénédicte Duval-Modeste, D. Noel, P. Bravard, Jean-François Gehanno, J. Goulle, A.-F. Cailleux, Hervé Levesque, Service de Médecine Interne [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Laboratoire d'Informatique, de Traitement de l'Information et des Systèmes (LITIS), Université Le Havre Normandie (ULH), Normandie Université (NU)-Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA), Equipe Traitement de l'information en Biologie Santé (TIBS - LITIS), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)-Université Le Havre Normandie (ULH), Unité de biostatistiques [CHU Rouen], Service de dermatologie [Rouen], Laboratoire Interuniversitaire de Biologie de la Motricité (LIBM ), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry]), Service de pneumologie, oncologie thoracique et soins intensifs respiratoires [Rouen], Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Hôpital Charles Nicolle [Rouen]-CHU Rouen, Groupe Hospitalier du Havre, Centre d'Investigation Clinique [CHU Rouen] (CIC Rouen), Hôpital Charles Nicolle [Rouen]-CHU Rouen, Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Département d'épidémiologie et de promotion de la santé [Rouen]
Subjects: Male, 0301 basic medicine, medicine.medical_specialty, Occupational risk, Smoking habit, [SDV]Life Sciences [q-bio], Immunology, chemistry.chemical_element, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, Metals, Heavy, Occupational Exposure, Internal medicine, Female patient, Environmental factors, Humans, Immunology and Allergy, Medicine, skin and connective tissue diseases, 030203 arthritis & rheumatology, Cadmium, Scleroderma, Systemic, integumentary system, business.industry, Case-control study, Heavy metals, Environmental Exposure, 3. Good health, Crystalline silica, 030104 developmental biology, chemistry, Case-Control Studies, Solvents, Systemic sclerosis, Female, Occupational exposure, business, Occupational factors
Abstract: This case control study assessed: 1) the relationship of systemic sclerosis (SSc) related to exposure to heavy metals; and 2) the risk of SSc related to occupational exposure in male and female patients.From 2005 to 2008, 100 patients with a definite diagnosis of SSc were included in the study; 3 age, gender, and smoking habit matched controls were selected for each patient. All SSc patients and controls underwent detection and quantification of heavy metal traces in hair samples, using multi-element inductively coupled plasma mass spectrometry (ICP-MS).SSc patients exhibited higher median levels of the following metals: antimony (p=0.001), cadmium (p=0.0003), lead (p=0.02), mercury (p=0.02), molybdenum (p=0.04), palladium (p0.0001) and zinc (p=0.0003). A marked association between SSc and occupational exposure was further found for: 1) antimony (p=0.008) and platinum (p=0.04) in male patients; and 2) antimony (p=0.02), cadmium (p=0.001), lead (p=0.03), mercury (p=0.03), palladium (p=0.0003) and zinc (p=0.0001) in female patients CONCLUSION: The results show the impact of occupational risk factors in the development of SSc for: antimony, cadmium, lead, mercury, molybdenum, palladium and zinc. Thus, occupational exposure should be systematically checked in all SSc patients at diagnosis. Finally, the association between SSc and occupational exposure may be variable according to patients' gender.
Published: 2017
Full Text: View/download PDF

16. Ischemic Digital Ulcers Affect Hand Disability and Pain in Systemic Sclerosis

Author: Agnès Sparsa, Catherine Lok, Christian Agard, Luc Mouthon, Patrick H. Carpentier, Virginie Gressin, Alice Bérezné, Elisabeth Diot, Marie-Aleth Richard, Anne Bénédicte Duval-Modeste, Patrick Jego, Eclipse Study Investigators, Aurélie Khau Van Kien, Eve Puzenat, Eric Hachulla, and Pierre Clerson
Subjects: Adult, Male, medicine.medical_specialty, Visual analogue scale, Immunology, Pain, Affect (psychology), Fingers, Raynaud phenomenon, Disability Evaluation, Rheumatology, Internal medicine, Skin Ulcer, medicine, Humans, Immunology and Allergy, In patient, Prospective Studies, Aged, Scleroderma, Systemic, Hand function, business.industry, Mean age, Middle Aged, Bosentan, Surgery, Cohort, Female, business, medicine.drug
Abstract: Objective.Ischemic digital ulcers (DU) are frequent and severe complications of systemic sclerosis (SSc). The purpose of our study was to assess the effect of DU on hand disability and pain in patients with SSc.Methods.The Evaluation of the Impact of Recurrent Ischemic DU on Hand Disability in Patients with SSc (ECLIPSE) is a prospective, multicenter, noninterventional study with a 2-year followup. Patients with SSc who experienced at least 1 DU in the previous year and received bosentan therapy were included between October 2009 and March 2011. This cohort is described at the time of inclusion.Results.There were 190 patients (132 females) from 53 centers. Mean age ± SD was 43 ± 15 years at SSc diagnosis and 53 ± 15 years at inclusion. In 105 patients (56.2%), DU were the first non-Raynaud symptoms of SSc. The mean time interval between the occurrence of Raynaud phenomenon and the first DU episode was 6.6 ± 9.1 years. The mean numbers of active DU and fingers affected per patient for both hands were 2.3 ± 1.8 and 2.2 ± 1.6, respectively. Presence of active DU at inclusion was significantly associated with pain and impaired hand function: Visual Analog Scale for pain (0 to 10) was 6.2 ± 2.6 versus 2.5 ± 2.4 (p < 0.0001) and Cochin Hand Function Scale for hand disability (0 to 90) was 38 ± 20 versus 25 ± 19 (p < 0.0001), respectively.Conclusion.DU represent a major sign of SSc, often affecting multiple fingers and both hands. They are significantly associated with pain and hand disability.
Published: 2014
Full Text: View/download PDF

17. PCN1 PROGNOSTIC FACTORS ASSOCIATED WITH REAL WORLD PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN PATIENTS WITH BRAF V600 MUTATION-POSITIVE ADVANCED MELANOMA TREATED WITH COBIMETINIB COMBINED WITH VEMUIRAFENIB, USING SURVIVAL DECISION TREE TECHNIQUE

Author: T. Vauléon, Anne-Bénédicte Duval-Modeste, D. Perol, M. Gilberg, R. Niarra, D Pau, L. El Adaoui, Y. Lelarge, Christine Mateus, and Nicolas Meyer
Subjects: Oncology, Cobimetinib, medicine.medical_specialty, business.industry, Health Policy, Public Health, Environmental and Occupational Health, Decision tree, chemistry.chemical_compound, chemistry, Internal medicine, BRAF V600 Mutation, Overall survival, Medicine, In patient, Progression-free survival, business, Advanced melanoma
Published: 2019
Full Text: View/download PDF

18. Prospective study to evaluate the association between systemic sclerosis and occupational exposure and review of the literature

Author: Isabelle Marie, P. Bravard, A.-F. Cailleux, S. Dominique, M. Bubenheim, Pascal Joly, Hervé Levesque, P. Lagoutte, Jacques Benichou, Anne-Bénédicte Duval-Modeste, J. Weber, Jean-François Gehanno, and D. Noel
Subjects: Male, medicine.medical_specialty, Chlorinated solvents, Smoking habit, Immunology, Cumulative Exposure, Risk Factors, Occupational Exposure, Hair dyes, Female patient, medicine, Humans, Immunology and Allergy, Prospective Studies, skin and connective tissue diseases, Prospective cohort study, Scleroderma, Systemic, integumentary system, business.industry, Middle Aged, Silicon Dioxide, Dermatology, Case-Control Studies, Aromatic solvents, Solvents, Physical therapy, Female, Occupational exposure, business
Abstract: Systemic sclerosis (SSc) has complex pathogenesis and likely multifactorial causes. Environmental exposures have been suggested to play a role in SSc pathogenesis, including occupational exposure to pollutants and chemicals as well as use of drugs leading to modulation of immune response. Thus, this case-control study aimed to assess: the relationship between SSc and occupational exposure; and the risk of SSc related to occupational exposure in male and female patients.From 2005 to 2008, 100 patients with a definite diagnosis of SSc were included in the study; 3 age, gender, and smoking habits matched controls were selected for each patient. A committee of experts evaluated blindly occupational exposure to crystalline silica, white spirit, organic solvents, ketones, welding fumes, epoxy resins, and pesticides; an occupational exposure score was calculated for all subjects. Our findings were compared with previous data in the literature.Increased ORs for SSc were found for: crystalline silica (p0.0001), white spirit (p0.0001), aromatic solvents (p=0.0002), chlorinated solvents (p=0.014), trichlorethylene (p=0.044), ketones (p=0.002) and welding fumes (p=0.021). Elevated risk associated with high final cumulative score in SSc was observed for: crystalline silica, white spirit, chlorinated solvents, trichlorethylene, aromatic solvents, any type of solvents, ketones and welding fumes. A marked association between SSc and occupational exposure was further found for: 1) crystalline silica, chlorinated solvents, trichloroethylene, white spirit, ketones and welding fumes in male patients; and 2) white spirit, aromatic solvents, any type of solvent and ketones in female patients. Finally, we did not find an association between SSc and: 1) the use of drugs that have been speculated to play a role in SSc onset (anorexigens, pentazocine, bromocriptine, l-tryptophan); 2) implants - that are prosthesis, silicone implants, and contact lenses; and 3) dyeing hair. In the literature, SSc has been associated with occupational exposure to silica and solvents, while the association between SSc and specific organic solvents and welding fumes has been anecdotally reported.The following occupational factors have an impact in the development of SSc: crystalline silica, white spirit, aromatic solvents, chlorinated solvents, trichlorethylene, ketones and welding fumes. The risk of SSc appears to be markedly associated with high cumulative exposure. Finally, the association between SSc and occupational exposure may be variable according to gender.
Published: 2014
Full Text: View/download PDF

19. Évolution de l’incidence et de la mortalité du mélanome en Seine-Maritime sur une période de 20ans

Author: M.-L. Roquet, J. Ziade, P. Chenal, H. Bokanowski, T. Ducastelle, A. Pellerin, Pascal Joly, Jacques Benichou, C. Boivin, J. Gremain, Philippe Courville, C. Corven, J.-M. Vaquer, C. De Mauroy, Anne-Bénédicte Duval-Modeste, C. Le Blanc, and F. Dalibard
Subjects: Gynecology, medicine.medical_specialty, business.industry, Incidence (epidemiology), medicine, Dermatology, business
Abstract: Resume Introduction Le but de cette etude etait d’evaluer l’evolution de l’incidence et de la mortalite du melanome (MM) en Seine-Maritime pendant une periode de 20 ans. Methodes Nous avons collige retrospectivement les comptes-rendus anatomopathologiques des cas de MM sur trois periodes espacees chacune de dix ans (1988–1989, 1998–1999, 2008–2009) aupres des laboratoires d’anatomopathologie de Seine-Maritime. Les taux d’incidence et de mortalite ont ete calcules a partir des donnees de l’Insee et de l’Inserm. Resultats En 20 ans, l’incidence du MM a augmente de 8,6 a 21,2 cas/100 000 habitants/an (+147 %, p p = 0,0003). L’incidence des MM invasifs a augmente de +110 % et celle des MM in situ de +456 %. L’incidence des MM invasifs et le taux de mortalite ont surtout augmente pendant les dix premieres annees : +62 % ( p p = 0,01), beaucoup moins les dix dernieres annees : +30 % ( p = 0,0007) et +22 % ( p = 0,22). Ce ralentissement de l’augmentation d’incidence des MM invasifs et de la mortalite qui y est liee a ete encore plus marque chez les femmes pendant les dix dernieres annees (+17 % et +9 % respectivement), tandis que ces taux ont continue d’augmenter chez les hommes (+49 % et +35 % respectivement). A l’inverse, l’incidence des MM in situ a surtout augmente ces dix dernieres annees (+257 %). Conclusion Le taux d’incidence des MM invasifs et le taux de mortalite des MM n’ont que peu augmente ces dix dernieres annees en Seine-Maritime, tandis que l’incidence des MM in situ a continue de fortement augmenter.
Published: 2013
Full Text: View/download PDF

20. Successful use of dabrafenib after the occurrence of drug rash with eosinophilia and systemic symptoms (DRESS) induced by vemurafenib

Author: Pascal Joly, C. Pinard, A. Samain, C. Mignard, Anne-Bénédicte Duval-Modeste, Service de dermatologie [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Physiopathologie, Autoimmunité, maladies Neuromusculaires et THErapies Régénératrices (PANTHER), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rouen Normandie (UNIROUEN), and Normandie Université (NU)-Normandie Université (NU)
Subjects: medicine.medical_specialty, [SDV]Life Sciences [q-bio], Dermatology, Article, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, medicine, Drug rash, lcsh:Dermatology, Eosinophilia, dabrafenib, Vemurafenib, ComputingMilieux_MISCELLANEOUS, business.industry, Dabrafenib, lcsh:RL1-803, drug rash with eosinophilia and systemic symptoms, 3. Good health, DRESS, drug rash with eosinophilia and systemic symptoms, 030220 oncology & carcinogenesis, vemurafenib, medicine.symptom, DRESS, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology, medicine.drug
Abstract: International audience
Published: 2017
Full Text: View/download PDF

21. Phase II Study of Cetuximab As First-Line Single-Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin

Author: Eve Maubec, Peter Petrow, Isabelle Scheer-Senyarich, Pierre Duvillard, Ludovic Lacroix, Julien Gelly, Agnès Certain, Xavier Duval, Béatrice Crickx, Valérie Buffard, Nicole Basset-Seguin, Pierre Saez, Anne-Bénédicte Duval-Modeste, Henri Adamski, Sandrine Mansard, Florent Grange, Anne Dompmartin, Sandrine Faivre, France Mentré, and Marie-Françoise Avril
Subjects: Adult, Male, Oncology, Cancer Research, medicine.medical_specialty, Skin Neoplasms, Population, Cetuximab, Phases of clinical research, Antineoplastic Agents, Antibodies, Monoclonal, Humanized, Internal medicine, Carcinoma, medicine, Humans, education, Survival rate, Aged, Aged, 80 and over, education.field_of_study, business.industry, Antibodies, Monoclonal, Middle Aged, medicine.disease, Rash, Surgery, Survival Rate, Treatment Outcome, Epidermoid carcinoma, Response Evaluation Criteria in Solid Tumors, Lymphatic Metastasis, Carcinoma, Squamous Cell, Female, medicine.symptom, business, Follow-Up Studies, medicine.drug
Abstract: Purpose To evaluate the efficacy and safety of cetuximab, a monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR), as a first-line monotherapy in patients with unresectable squamous cell carcinoma of the skin (SCCS). Patients and Methods Thirty-six patients received cetuximab (initial dose of 400 mg/m2 followed by subsequent weekly doses of 250 mg/m2) for at least 6 weeks with a 48-week follow-up. The primary end point was the disease control rate (DCR) at 6 weeks (according to Response Evaluation Criteria in Solid Tumors [RECIST] criteria). Secondary end points included best response rate, overall survival, progression-free survival (PFS), and toxicity assessment. Association of treatment efficacy with RAS mutations or FcγR genotypes was investigated. Results Median age of the study population was 79 years. DCR at 6 weeks was obtained in 25 of 36 patients (69%; 95% CI, 52% to 84%) of the intention-to-treat population. The best responses were eight partial responses and two complete responses. There were no cetuximab-related deaths. There were three related serious adverse events: two grade 4 infusion reactions and one grade 3 interstitial pneumopathy. Grade 1 to 2 acne-like rash occurred in 78% of patients and was associated with prolonged PFS. One HRAS mutation was identified. Combined FcγRIIa-131H/H and/or FcγRIIIa-158V/V polymorphisms were not associated with the clinical outcomes. Conclusion As a first-line treatment in patients with unresectable SCCS, cetuximab achieved 69% DCR. A randomized phase III trial is warranted to confirm that cetuximab may be considered as a therapeutic option especially in elderly patients. The low frequency of RAS mutations in SCCS makes SCCS tumors attractive for EGFR inhibition.
Published: 2011
Full Text: View/download PDF

22. Pneumopathie interstitielle subaiguë après traitement d’un psoriasis par infliximab

Author: Aude Roussel, Sandy Leger, Anne-Bénédicte Duval-Modeste, Manuel Etienne, François Caron, and Luc Thiberville
Subjects: Gynecology, medicine.medical_specialty, Lung disease, business.industry, Respiratory disease, medicine, Interstitial pneumonia, Dermatology, medicine.disease, business, Infliximab, Interstitial pneumonitis, medicine.drug
Abstract: Resume Introduction Les inhibiteurs du « Tumor Necrosis Factor alpha » (anti-TNFα) sont utilises de plus en plus frequemment dans le traitement du psoriasis severe. La pneumopathie d’hypersensibilite en est une complication rare, peu connue des dermatologues, souvent mortelle. Observation Une femme de 68 ans, traitee par infliximab pour un psoriasis severe, etait hospitalisee trois mois apres le debut du traitement pour une dyspnee febrile d’installation subaigue, associee a une toux seche et des douleurs basithoraciques. Les examens biologiques montraient un syndrome inflammatoire et une hypoxemie. La tomodensitometrie objectivait des troubles ventilatoires des deux bases pulmonaires, avec foyers de condensation parenchymateuse et epanchements pleuraux bilateraux. Le lavage bronchoalveolaire ainsi que les autres prelevements microbiologiques etaient negatifs. Un traitement probabiliste par amoxicilline/acide clavulanique et spiramycine etait inefficace. Le diagnostic d’alveolite allergique etait evoque et une corticotherapie permettait une amelioration de la dyspnee, des echanges gazeux et des images radiologiques. Discussion La pneumopathie d’hypersensibilite est une complication pulmonaire possible des anti-TNFα, frequemment mortelle. Nous rapportons le premier cas de pneumopathie interstitielle secondaire a un traitement par infliximab instaure pour un psoriasis severe, en l’absence d’autre medicament pneumotoxique imputable. Le tableau clinique est d’installation aigue ou sub-aigue, associant une toux seche, une dyspnee et une febricule. Le diagnostic d’alveolite allergique a l’infliximab n’est retenu qu’apres elimination des autres causes de pneumopathie interstitielle. Conclusion Les anti-TNFα connaissent des indications croissantes en dermatologie. Il importe d’avoir bien a l’esprit leurs complications rares mais graves, telles les pneumopathies d’hypersensibilite.
Published: 2011
Full Text: View/download PDF

23. Cetuximab in patients with unresectable cutaneous squamous cell carcinoma is safe and effective: A real-life analysis

Author: Stéphane Dalle, A. Picard, Julien Viotti, Patrick Combemale, Nicolas Dupin, C. Dutriaux, Henri Montaudié, Frederic Peyrade, F. Brunet-Possenti, J. De Quatrebarbes, Anne-Bénédicte Duval-Modeste, C. Robert, Laurent Mortier, Gilles Poissonnet, Maria Kogay, and A. Stefan
Subjects: Oncology, medicine.medical_specialty, Cutaneous squamous cell carcinoma, Cetuximab, business.industry, 030503 health policy & services, Hematology, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, In patient, 030212 general & internal medicine, 0305 other medical science, business, medicine.drug
Published: 2018
Full Text: View/download PDF

24. Myopathies inflammatoires et anticorps anti-PM-Scl : à propos d’une série et revue de la littérature

Author: Anne-Bénédicte Duval-Modeste, Fabienne Jouen, L. Lahaxe, Olivier Vittecoq, Isabelle Marie, H. Levesque, and K.P. Tiev
Subjects: Gynecology, medicine.medical_specialty, business.industry, Gastroenterology, Internal Medicine, medicine, business
Abstract: Resume Propos Le but de notre etude etait de determiner la prevalence des anticorps anti-PM-Scl dans le cadre de la recherche d’anticorps antinucleaires. Surtout, nous avons analyse la signification clinique et evolutive des anticorps anti-PM-Scl chez les patients atteints de polymyosite ou de dermatomyosite isolee. Methodes Nous avons realise une etude de la prevalence des anticorps anti-PM-Scl sur 9064 demandes successives de recherche d’anticorps antinucleaires adressees au laboratoire d’immunologie du centre hospitalier universitaire de Rouen entre 2004 et 2006. Nous avons ensuite analyse les caracteristiques cliniques et evolutives sous traitement des patients ayant une polymyosite/dermatomyosite. Resultats Sur 9064 demandes de recherche d’anticorps antinucleaires, la detection a ete positive dans 3263 cas (36 %) ; des anticorps anti-PM-Scl ont ete detectes chez neuf patients, soit 0,1 % de l’ensemble des serums, 0,2 % des serums avec anticorps antinucleaires positifs et 1,2 % des serums avec anticorps antinucleaires solubles. Parmi les neuf patients avec anticorps anti-PM-Scl, trois avaient une dermatomyosite et un presentait une polymyosite ; chez ces patients, les localisations viscerales severes de la dermatomyosite/polymyosite etaient les suivantes : hypoventilation alveolaire (n = 2) et atteinte œsophagienne (n = 1). De plus, deux patients avaient une neoplasie associee a la maladie musculaire. Conclusion Contrairement aux precedentes publications qui mentionnaient le bon pronostic des dermatomyosites/polymyosites avec anticorps anti-PM-Scl, notre travail suggere que ce type de myopathie inflammatoire pourrait etre greve d’une morbidite importante. En effet, ces patients presentaient frequemment des localisations pulmonaires et œsophagiennes, ainsi qu’une neoplasie associee ; ainsi, le sous-groupe de patients atteints de dermatomyosite/polymyosite avec anticorps anti-PM-Scl devrait beneficier d’explorations pneumologiques et digestives de meme que de la recherche d’une neoplasie sous-jacente lors du bilan initial et du suivi evolutif de la maladie.
Published: 2010
Full Text: View/download PDF

25. Syndrome d’hypersensibilité médicamenteuse à l’imatinib

Author: Anne-Bénédicte Duval-Modeste, Nathalie Contentin, J. Goldman, Philippe Musette, A. Lambert, Philippe Courville, and Pascal Joly
Subjects: Gynecology, medicine.medical_specialty, Imatinib mesylate, business.industry, Immunopathology, medicine, Imatinib, Dermatology, Skin pathology, business, medicine.drug, Surgery
Abstract: Resume Introduction L’imatinib (Glivec®) est un inhibiteur des tyrosines kinases utilise dans certaines leucemies. Nous rapportons une observation de syndrome d’hypersensibilite medicamenteuse ou drug reaction with eosinophilia and systemic symptoms (DRESS) induit par l’imatinib. Observation Une femme de 77 ans, atteinte d’une leucemie myeloide chronique, a ete traitee par de l’imatinib et de l’allopurinol. A j19, elle a developpe une eruption cutanee polymorphe febrile, avec des erosions buccales, associee a un œdeme du visage, une polyadenopathie et une hypereosinophilie sanguine. L’examen histologique cutane etait en faveur d’une toxidermie. L’evolution a ete favorable en 15 jours apres l’arret des deux medicaments. Une reintroduction de l’imatinib trois mois apres, necessitee par l’evolutivite de la leucemie myeloide chronique, a entraine une recidive du DRESS dans les 12 heures. Discussion L’allopurinol a ete arrete definitivement devant une imputabilite plus frequente. L’imatinib a ete reintroduit apres avoir considere le rapport benefice/risque et en connaissance des effets cutanes secondaires frequents, bien qu’un seul cas de DRESS ait ete publie jusqu’alors. Selon les criteres de Begaud et al. l’imputabilite de l’imatinib, qui etait plausible initialement (I2) chez cette malade, est devenue vraisemblable apres l’epreuve de reintroduction (I3). Cette observation illustre le fait que l’imatinib est un medicament potentiellement inducteur de DRESS.
Published: 2008
Full Text: View/download PDF

26. Unusual presentation of oropharyngeal Kaposi's sarcoma

Author: Danièle Dehesdin, Anne Bénédicte Duval-Modeste, Arnaud François, Christophe Van Haverbeke, Emmanuel Babin, and Olivier Choussy
Subjects: Male, Larynx, medicine.medical_specialty, Hematocrit, otorhinolaryngologic diseases, medicine, Humans, Sarcoma, Kaposi, Kaposi's sarcoma, Lymph node, Nose, Hoarseness, medicine.diagnostic_test, business.industry, Middle Aged, medicine.disease, Dysphagia, Surgery, Oropharyngeal Neoplasms, medicine.anatomical_structure, Otorhinolaryngology, Cervical lymph nodes, Sarcoma, medicine.symptom, Deglutition Disorders, business
Abstract: Background. The aim of this article is to focus ear, nose, and throat (ENT) practitioners on a pathology rarely seen within the head and neck mucosa. Methods. A 62-year-old black African man was referred to our ENT department for dysphagia and hoarseness. Physical ENT examination revealed a smooth normal mucosal mass on the left lateral pharyngeal wall, which masked the inlet of the larynx, and bilateral cervical lymph nodes but no other mucosal lesions. Anti–human immunodeficiency virus antibodies were found to be negative. Hemoglobin, hematocrit, white blood cell count, and platelet count were normal. Serum protein electrophoresis was also normal. A CT scan confirmed the lesion and lymph node involvement. Treatment consisted of a transoral endoscopic resection with ligature of the pedicle, with the patient under general anesthesia. The patient's improved medical condition permitted 11 cycles of bleomycin (15 mg/3 weeks). Results. A 5-month fibroscopic follow-up control showed no recurrence, and total clinical regression was observed after 1 year. Three years later, all ENT lesions had disappeared, with no adenopathy or mucosal lesions. Conclusion. Kaposi's sarcoma is a pathology that the ENT practitioner must keep in mind when patients present with a laryngopharyngeal mass. The symptomatic cases were all surgically treated; however, death subsequently occurred. © 2007 Wiley Periodicals, Inc. Head Neck 2008
Published: 2008
Full Text: View/download PDF

27. Association of occupational exposure with features of systemic sclerosis

Author: Hervé Levesque, Isabelle Marie, Jean-François Gehanno, D. Noel, M. Bubenheim, Pascal Joly, Anne-Bénédicte Duval-Modeste, Jean-François Ménard, Jacques Benichou, Stéphane Dominique, P. Bravard, Service de Médecine Interne [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Physiopathologie, Autoimmunité, maladies Neuromusculaires et THErapies Régénératrices (PANTHER), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Unité de biostatistiques [CHU Rouen], Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Service de dermatologie [Rouen], Service de pneumologie, oncologie thoracique et soins intensifs respiratoires [Rouen], Normandie Université (NU)-Normandie Université (NU)-Hôpital Charles Nicolle [Rouen]-CHU Rouen, Spatio-temporal information systems (STEAMER), Laboratoire d'Informatique de Grenoble (LIG), Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Institut National Polytechnique de Grenoble (INPG)-Centre National de la Recherche Scientifique (CNRS)-Université Pierre Mendès France - Grenoble 2 (UPMF)-Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Institut National Polytechnique de Grenoble (INPG)-Centre National de la Recherche Scientifique (CNRS)-Université Pierre Mendès France - Grenoble 2 (UPMF)-Université Joseph Fourier - Grenoble 1 (UJF), Laboratoire d'Informatique, de Traitement de l'Information et des Systèmes (LITIS), Université Le Havre Normandie (ULH), Normandie Université (NU)-Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA), and Hôpital Charles Nicolle [Rouen]-CHU Rouen
Subjects: Adult, Male, Vital capacity, medicine.medical_specialty, Pathology, systemic sclerosis, [SDV]Life Sciences [q-bio], education, Dermatology, crystalline silica, Gastroenterology, FEV1/FVC ratio, DLCO, Occupational Exposure, Internal medicine, Humans, Medicine, cancer, Prospective Studies, occupational factors, Prospective cohort study, skin and connective tissue diseases, health care economics and organizations, Aged, interstitial lung disease, Scleroderma, Systemic, integumentary system, business.industry, Microangiopathy, Interstitial lung disease, Odds ratio, Middle Aged, Silicon Dioxide, medicine.disease, Confidence interval, 3. Good health, solvents, Dermatitis, Occupational, Scleroderma, Diffuse, digital ulcers, Female, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: Background Occupational exposure is reported as playing a substantial causative role in systemic sclerosis (SSc). Objective We sought to compare the characteristics of SSc in patients with and without occupational exposure to crystalline silica/solvents. Methods In all, 142 patients with SSc were enrolled in this prospective study. An expert committee performed blind evaluation of occupational exposure to crystalline silica/solvents. Results Patients exposed to crystalline silica more often exhibited: diffuse cutaneous SSc ( P = .02), digital ulcers ( P = .05), interstitial lung disease ( P = .0004), myocardial dysfunction ( P = .006), and cancer ( P = .06). Patients exposed to solvents more frequently developed: diffuse cutaneous SSc ( P = .001), digital ulcers ( P = .01), interstitial lung disease ( P = .02), myocardial dysfunction ( P = .04), and cancer ( P = .003); in addition, these patients were more frequently anti-Scl 70 positive and anticentromere negative. Under multivariate analysis, significant factors for SSc associated with exposure to silica/solvents were: male gender (odds ratio 19.31, 95% confidence interval 15.34-69.86), cancer (odds ratio 5.97, 95% confidence interval 1.55-23.01), and digital ulcers (odds ratio 2.42, 95% confidence interval 1.05-5.56). Limitations The cohort originated from a single geographic region. Conclusion Occupational exposure to crystalline silica/solvents is correlated with more severe forms of SSc characterized by: diffuse cutaneous involvement, interstitial lung disease, general microangiopathy (digital ulcers and myocardial dysfunction), and association with cancer. Occupational exposure should be systematically checked in all patients with SSc, as exposed patients seem to develop more severe forms of SSc.
Published: 2015
Full Text: View/download PDF

28. Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome à l’oxcarbazépine mimant un choc septique

Author: Jean-Charles Chakarian, Guy Bonmarchand, Pascal Joly, Christophe Girault, Anne-Bénédicte Duval-Modeste, and Gaetan Beduneau
Subjects: Allergy, medicine.medical_specialty, Septic shock, business.industry, medicine.medical_treatment, Diagnostico diferencial, General Medicine, medicine.disease, Dermatology, Anticonvulsant, Immunopathology, Immunology, medicine, Drug rash, Eosinophilia, medicine.symptom, Oxcarbazepine, business, medicine.drug
Published: 2010
Full Text: View/download PDF

29. Syndrome d’hypersensibilité médicamenteuse à la gabapentine

Author: C. Courville, Philippe Musette, J. Goldman, N. Massy, Anne-Bénédicte Duval-Modeste, Pascal Joly, and A. Rabehenoina
Subjects: Allergy, medicine.medical_specialty, Gabapentin, business.industry, medicine.medical_treatment, Analgesic, Dermatology, medicine.disease, Anticonvulsant, Immunopathology, medicine, business, medicine.drug
Published: 2008
Full Text: View/download PDF

30. Sentinel Node Status and Immunosuppression: Recurrence Factors in Localized Merkel Cell Carcinoma

Author: P.-E. Stoebner, Emeline Kubica, Christophe Bedane, Catherine Lok, Anne-Bénédicte Duval-Modeste, Thomas Jouary, Christina Mateus, Sandrine Mansard, Khaled Ezzedine, Florence Granel-Brocard, Marie-Thérèse Leccia, Anne Dompmartin, Jean-Philippe Lacour, Bernard Guillot, Philippe Saiag, Stéphane Dalle, Abou Diallo, Cécile Pagès, François Aubin, Sophie Dalac, Herrada, Anthony, Service de dermatologie Hôpital Saint-André Bordeaux, CHU Bordeaux [Bordeaux], Centre Léon Bérard [Lyon], Hôpital Saint-Louis, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Service de Dermatologie [Rouen], Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Pathogénèse et contrôle des infections chroniques (PCCI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), CHU Clermont-Ferrand, Hôpital Ambroise Paré [AP-HP], Département de dermatologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Service de Dermatologie [CHU Limoges], CHU Limoges, Service de Dermatologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Service de Dermatologie [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Service de Dermatologie et Allergologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Service de dermatologie [CHU d'Amiens-Picardie], CHU Amiens-Picardie, Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Institut des Biomolécules Max Mousseron [Pôle Chimie Balard] (IBMM), Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM)-Institut de Chimie du CNRS (INC)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Service de Dermatologie [Nice], Hôpital Archet 2 [Nice] (CHU), CHU Grenoble, Institut de Santé Publique, d'Epidémiologie et de Développement (ISPED), Université Bordeaux Segalen - Bordeaux 2, Oncologie dermatologique, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Charles Nicolle [Rouen]-CHU Rouen, CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Université de Caen Normandie (UNICAEN), Normandie Université (NU), and Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC)-Université de Montpellier (UM)-Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM)
Subjects: Male, Oncology, Pathology, Skin Neoplasms, Time Factors, medicine.medical_treatment, Kaplan-Meier Estimate, 030207 dermatology & venereal diseases, Merkel cell carcinoma, 0302 clinical medicine, Risk Factors, Medicine, Aged, 80 and over, education.field_of_study, medicine.diagnostic_test, Immunosuppression, General Medicine, Middle Aged, Sentinel node, 3. Good health, Treatment Outcome, Lymphatic Metastasis, 030220 oncology & carcinogenesis, Female, France, Adult, medicine.medical_specialty, Population, Sentinel lymph node, Dermatology, Risk Assessment, Disease-Free Survival, Immunocompromised Host, Young Adult, 03 medical and health sciences, Sex Factors, Predictive Value of Tests, Internal medicine, Biopsy, Humans, education, radiotherapy, Aged, Neoplasm Staging, Proportional Hazards Models, Retrospective Studies, Chi-Square Distribution, Sentinel Lymph Node Biopsy, business.industry, Retrospective cohort study, [SDV.MHEP.DERM] Life Sciences [q-bio]/Human health and pathology/Dermatology, medicine.disease, Carcinoma, Merkel Cell, Radiation therapy, Logistic Models, sentinel node, Multivariate Analysis, Feasibility Studies, Lymph Nodes, Neoplasm Recurrence, Local, business, prognostic, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology
Abstract: International audience; The prognostic value of the sentinel lymph node in Merkel cell carcinoma (MCC) has been examined previously in heterogeneous retrospective studies. The current retrospective study included a homogeneous population of patients with a localized MCC, all staged with sentinel lymph node biopsy. Factors associated with 3-year progression-free survival were analysed using logistic regression. The sentinel lymph node was positive in 32% of patients. The recurrence rate was 26.9%. In first analyses (n = 108), gender (p = 0.0115) and the presence of immunosuppression (p = 0.0494) were the only significant independent factors. In further analyses (n = 80), excluding patients treated with regional radiotherapy, sentinel lymph node status was the only significant prognostic factor (p = 0.0281). Immunosuppression and positive sentinel lymph node are associated with a worse prognosis in patients with MCC. Nodal irradiation impacts on the prognostic value of the sentinel lymph node status.
Published: 2014
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources

Refine your results

30 results on '"Anne-Bénédicte Duval-Modeste"'

1. Intralesional rituximab treatment for atypical refractory granuloma faciale

2. Effectiveness and safety of nivolumab in patients with advanced melanoma: A multicenter, observational study

3. Cetuximab is efficient and safe in patients with advanced cutaneous squamous cell carcinoma: a retrospective, multicentre study

4. Lymphome cérébral primitif après immunothérapie d’un mélanome métastatique

5. Cemiplimab for locally advanced and metastatic cutaneous squamous-cell carcinomas: Real-life experience from the French CAREPI study group

6. Panniculitis in a Woman With Opportunistic Pulmonary Coinfection by Pneumocystis jirovecii and Cryptococcus neoformans: 18F-FDG PET/CT Revealing the Infection and Assessing Treatment Response

7. Anti-PD-1 induced collagenous colitis in metastatic melanoma: a rare severe adverse event

8. Controlling the digital ulcerative disease in systemic sclerosis is associated with improved hand function

9. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort

10. A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, Leg Type

11. Simultaneous long-lasting regression of multiple nevi and melanoma metastases after ipilimumab therapy

12. Ipilimumab-induced severe meningoradiculitis

13. Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma

14. Efficacy and Tolerance of Anti-Tumor Necrosis Factor α Agents in Cutaneous Sarcoidosis: A French Study of 46 Cases

15. Systemic sclerosis and exposure to heavy metals: A case control study of 100 patients and 300 controls

16. Ischemic Digital Ulcers Affect Hand Disability and Pain in Systemic Sclerosis

17. PCN1 PROGNOSTIC FACTORS ASSOCIATED WITH REAL WORLD PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN PATIENTS WITH BRAF V600 MUTATION-POSITIVE ADVANCED MELANOMA TREATED WITH COBIMETINIB COMBINED WITH VEMUIRAFENIB, USING SURVIVAL DECISION TREE TECHNIQUE

18. Prospective study to evaluate the association between systemic sclerosis and occupational exposure and review of the literature

19. Évolution de l’incidence et de la mortalité du mélanome en Seine-Maritime sur une période de 20ans

20. Successful use of dabrafenib after the occurrence of drug rash with eosinophilia and systemic symptoms (DRESS) induced by vemurafenib

21. Phase II Study of Cetuximab As First-Line Single-Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin

22. Pneumopathie interstitielle subaiguë après traitement d’un psoriasis par infliximab

23. Cetuximab in patients with unresectable cutaneous squamous cell carcinoma is safe and effective: A real-life analysis

24. Myopathies inflammatoires et anticorps anti-PM-Scl : à propos d’une série et revue de la littérature

25. Syndrome d’hypersensibilité médicamenteuse à l’imatinib

26. Unusual presentation of oropharyngeal Kaposi's sarcoma

27. Association of occupational exposure with features of systemic sclerosis

28. Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome à l’oxcarbazépine mimant un choc septique

29. Syndrome d’hypersensibilité médicamenteuse à la gabapentine

30. Sentinel Node Status and Immunosuppression: Recurrence Factors in Localized Merkel Cell Carcinoma

Catalog

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Journal

Database

Publisher

30 results on '"Anne-Bénédicte Duval-Modeste"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources